These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36545274)

  • 21. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer.
    Zhang Y; Wei J; Wang H; Xue X; An Y; Tang D; Yuan Z; Wang F; Wu J; Zhang J; Miao Y
    Oncol Rep; 2012 May; 27(5):1599-605. PubMed ID: 22322379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
    Meng Q; Shi S; Liang C; Liang D; Hua J; Zhang B; Xu J; Yu X
    Oncogene; 2018 Nov; 37(44):5843-5857. PubMed ID: 29980787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.
    Chen M; Jiang Y; Cai X; Lu X; Chao H
    Int Immunopharmacol; 2021 Sep; 98():107829. PubMed ID: 34119916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis.
    Chen H; Wei W; Guo Y; Liu A; Tong H; Wang Z; Tan W; Liu J; Lin S
    Oncol Rep; 2011 May; 25(5):1253-61. PubMed ID: 21305255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin increases the efficacy of gemcitabine in pancreatic cancer by modulating the PI3K/AKT/mTOR signaling pathway and reversing epithelial‑mesenchymal transition.
    Zhou H; Yun X; Shu Y; Xu K
    Oncol Lett; 2023 Mar; 25(3):101. PubMed ID: 36817049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
    Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
    Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4.
    Yu G; Jia B; Cheng Y; Zhou L; Qian B; Liu Z; Wang Y
    Am J Transl Res; 2017; 9(11):5048-5055. PubMed ID: 29218103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling.
    Sun L; Cao J; Chen K; Cheng L; Zhou C; Yan B; Qian W; Li J; Duan W; Ma J; Qi D; Wu E; Wang Z; Liu Q; Ma Q; Xu Q
    Int J Oncol; 2019 Jan; 54(1):98-110. PubMed ID: 30365057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Echinacoside (ECH) suppresses proliferation, migration, and invasion of human glioblastoma cells by inhibiting Skp2-triggered epithelial-mesenchymal transition (EMT).
    Shi S; Qin Y; Chen D; Deng Y; Yin J; Liu S; Yu H; Huang H; Chen C; Wu Y; Zou D; Wang Z
    Eur J Pharmacol; 2022 Oct; 932():175176. PubMed ID: 35995211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.
    Yao N; Chen Q; Shi W; Tang L; Fu Y
    Mol Carcinog; 2019 Jul; 58(7):1291-1302. PubMed ID: 30968979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p73 induction by Abrus agglutinin facilitates Snail ubiquitination to inhibit epithelial to mesenchymal transition in oral cancer.
    Sinha N; Meher BR; Naik PP; Panda PK; Mukhapadhyay S; Maiti TK; Bhutia SK
    Phytomedicine; 2019 Mar; 55():179-190. PubMed ID: 30668428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
    Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
    Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.
    Wang B; Shen C; Li Y; Zhang T; Huang H; Ren J; Hu Z; Xu J; Xu B
    Onco Targets Ther; 2019; 12():5751-5765. PubMed ID: 31410021
    [No Abstract]   [Full Text] [Related]  

  • 35. Emodin inhibits epithelial to mesenchymal transition in epithelial ovarian cancer cells by regulation of GSK-3β/β-catenin/ZEB1 signaling pathway.
    Hu C; Dong T; Li R; Lu J; Wei X; Liu P
    Oncol Rep; 2016 Apr; 35(4):2027-34. PubMed ID: 26820690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irisin reverses the IL-6 induced epithelial-mesenchymal transition in osteosarcoma cell migration and invasion through the STAT3/Snail signaling pathway.
    Kong G; Jiang Y; Sun X; Cao Z; Zhang G; Zhao Z; Zhao Y; Yu Q; Cheng G
    Oncol Rep; 2017 Nov; 38(5):2647-2656. PubMed ID: 29048621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
    Qiu F; Chen J; Cao J; Diao F; Huang P
    Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-494 acts as a tumor suppressor in pancreatic cancer, inhibiting epithelial-mesenchymal transition, migration and invasion by binding to SDC1.
    Yang Y; Tao X; Li CB; Wang CM
    Int J Oncol; 2018 Sep; 53(3):1204-1214. PubMed ID: 29956739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets.
    Zhang W; Chen H; Liu DL; Li H; Luo J; Zhang JH; Li Y; Chen KJ; Tong HF; Lin SZ
    Int J Oncol; 2013 Apr; 42(4):1189-96. PubMed ID: 23440366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer.
    Xi Y; Li T; Xi Y; Zeng X; Miao Y; Guo R; Zhang M; Li B
    Cancer Cell Int; 2022 Sep; 22(1):271. PubMed ID: 36050724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.